Overall, the reduction in breast cancer mortality after the implementation of screening mammography was not attributed to screening but to improved systemic therapy.44 Of note, there are exceptions, as breast cancer screening for carriers of BRCA1 and BRCA2 germline mutations is recommended and surveillance programs with proven efficiency exist.46 This evidence concerns the gene BRCA1 and breast cancer.